Two Strategies for Specialty Drug Savings—And How to Choose the Right One

Key Takeaways

• AFPs lower out‑of‑pocket costs but increase coordination complexity.
• In‑benefit optimization cuts waste without adding new vendors.
• Identify spend concentrations before selecting a savings model.
• Preserve therapy continuity to meet compliance and patient outcomes.
• Track patient impact beyond price to ensure program success.

Pulse Analysis

Rising specialty drug prices are reshaping the U.S. pharmaceutical landscape. In 2026, manufacturers raised prices on roughly 872 drugs, driving a median 4% increase that ripples through employer‑sponsored health plans. The surge forces plan sponsors to confront a dual challenge: containing escalating spend while maintaining uninterrupted access for members. Traditional benefit designs struggle to absorb these shocks, prompting a shift toward more nuanced cost‑management strategies that blend financial stewardship with clinical continuity.

Alternative funding programs (AFPs) have emerged as a popular lever for employers seeking immediate relief on high‑cost agents. By leveraging manufacturer assistance, copay‑offsets, or third‑party sourcing, AFPs can reduce patient out‑of‑pocket liabilities and blunt the impact of price spikes on overall spend. However, the upside comes with added operational complexity: multiple vendors, heightened documentation, and increased prescriber workload can strain existing workflows and raise audit risk. Successful AFP deployment demands clear guardrails, robust communication protocols, and a dedicated governance structure to keep therapy continuity intact.

In‑benefit optimization offers a contrasting, internally focused pathway. Rather than introducing new funding streams, this model mines inefficiencies within the current PBM ecosystem—eliminating duplicate therapies, curbing oversupply, and surfacing lower‑cost in‑network alternatives. By aligning savings with existing clinical workflows, sponsors can achieve measurable cost reductions without the administrative overhead of AFPs. A disciplined, data‑driven process—identifying spend hotspots, assessing waste signals, and monitoring patient outcomes—ensures that savings are both defensible and patient‑centric. For many employers, a hybrid approach that blends targeted AFPs for outlier spend with broader in‑benefit optimization delivers the most resilient, compliant, and sustainable cost‑containment strategy.